Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06315101
Status:
COMPLETED
Last Update Posted:
2024-03-18
First Post:
2024-03-07
Brief Title:
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma A Real-world Study in China
Sponsor:
Guangzhou University of Chinese Medicine
Organization:
Guangzhou University of Chinese Medicine
Study Overview
Official Title:
A Real-world Study of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to assess the effectiveness and safety of lenvatinib plus Chinese Herbal Medicine CHM for patients with uHCC in China
Detailed Description:
Liver resection is one of the most important treatments for hepatocellular carcinoma HCC However only a minority of patients have the opportunity to undergo surgery The development of systemic therapy has dramatically changed the management of unresectable HCC uHCC And lenvatinib garners a recommendation as the primary treatment for uHCC Many patients with uHCC in Asian countries seek complementary and alternative therapies with traditional Chinese medicine TCM However the impact of lenvatinib combined with CHM on uHCC patients remains unclear In this study we conducted a retrospective cohort study to assess the effectiveness and safety of lenvatinib plus CHM for patients with uHCC in China
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None